First out the gate

Antiviral play Ascletis comes out of the gate on HKEX at $2B valuation

As Ascletis Pharma Inc. (HKSE:1672) prepares for its trading debut on Aug. 1, Hong Kong Exchanges and Clearing Ltd. (HKEX) market watchers hope investor demand for biotech in the region can maintain momentum.

Ascletis priced its IPO on HKEX at HK$14 per share, according to a financial industry source familiar with the deal. The antiviral company is the first biotech to go public

Read the full 630 word article

User Sign In